Research
Molecular
Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.
Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.
StrongSupportsmedium confidence
Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.
Why this rating
The statement is based on the development status of clinical candidates.
Source
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Héctor Iván Saldívar-Cerón et al. · Scientia Pharmaceutica · 2025
DOI 10.3390/scipharm93020026
reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Orforglipron has advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.Strong
- Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, offer substantial potential due to their oral bioavailability and favorable gastrointestinal tolerability.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →